Immunodiagnostic launches first product in fertility portfolio
Specialty clinical laboratory diagnostic solutions company Immunodiagnostic Systems Holdings announced the launch of the IDS-iSYS 17-OH Progesterone assay in the European market - the first product released as part of its upcoming steroid hormones fertility portfolio.
FTSE AIM All-Share
728.67
15:45 15/11/24
Health Care Equipment & Services
10,430.75
15:44 15/11/24
Immunodiagnostic Systems Holdings
378.00p
15:49 12/07/21
The AIM-traded firm said the assay measures a patient’s 17-OH Progesterone level, and offers clinicians a non-invasive way to diagnose disorders of the adrenal gland or ovaries such as congenital adrenal hyperplasia or polycystic ovary syndrome.
Women with PCOS have higher than normal levels of 17-OH Progesterone, the company said, which can be a cause of infertility.
“As the only fully automated solution on the market, the IDS-iSYS 17-OH Progesterone assay allows laboratories to benefit from reduced time to first result for measurement of patient samples,” Immunodiagnostic’s board said in a statement.
It said the global market size of 17-OH Progesterone testing is estimated to be between £7m and £10m.